Table 1 Biopsychosocial descriptors of participants at Time 1
Variable | Subcategories | T1 Total initial sample Count (%) | T1 Subgroup who completed both timepoints Count (%) |
|---|---|---|---|
Gender | Male | 462 (62.3%) | 313 (63.7%) |
| Â | Female | 280 (37.7%) | 178 (36.3%) |
Psychotropic Polypharmacy | Â | Â | Â |
| Â | None or 1 type | 414 (55.8%) | 265 (54.0%) |
| Â | 2 or more types | 328 (44.2%) | 226 (46.0%) |
BPRS-C | Â | Â | Â |
|  | No/minimal symptoms (scores 18–30) | 566 (76.3%) | 380 (77.4%) |
| Â | Clinically relevant symptoms present (scores 31+) | 173 (23.7%) | 111 (22.6%) |
MADRS-C | Â | Â | Â |
|  | Subclinical (no to very mild symptoms) (scores 0–8) | 558 (75.2%) | 376 (76.6%) |
|  | Mild symptoms (scores 9–17) | 150 (20.2%) | 95 (19.3%) |
| Â | Moderate to Severe symptoms (scores 18+) | 34 (4.6%) | 20 (4.1%) |
ITAQ-C | Â | Â | Â |
|  | Poor insight (scores 0–7) | 264 (35.6%) | 174 (35.4%) |
|  | Moderate insight (scores 8–13) | 247 (33.3%) | 162 (33.0%) |
|  | Good insight (scores 14–22) | 231 (31.1%) | 155 (31.6%) |
SQoL Rating | Â | Â | Â |
| Â | Very poor | 9 (1.2%) | 5 (1.0%) |
| Â | Poor | 101 (13.6%) | 69 (14.1%) |
| Â | Neither poor nor good | 507 (68.3%) | 338 (68.8%) |
| Â | Good | 125 (16.8%) | 79 (16.1%) |
| Â | Very good | --- | --- |
| Â | Â | Median (IQR) | Median (IQR) |
Contemporary Age (years) |  | 38.5 (30.0–48.0) | 40.0 (31.0–49.0) |
Age of illness onset (years) |  | 24.0 (19.0–30.0) | 23.0 (20.0–30.0) |
SDS-C | Work/School | 4 (3–5) | 4 (3–5) |
SDS-C | Social | 4 (3–5) | 4 (3–5) |
SDS-C | Family | 4 (3–5) | 4 (2–5) |
Consumer satisfaction with current treatment |  | 4 (4–5) | 4 (4–5) |